Akari Therapeutics (AKTX) Competitors

$6.25 -0.33 (-5.02%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$6.26 +0.01 (+0.16%)

As of 05/8/2026 05:22 PM Eastern

AKTX vs. AYTU, DYAI, VIRI, ABVC, and MRKR

Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Aytu BioPharma (AYTU), Dyadic International (DYAI), Virios Therapeutics (VIRI), ABVC BioPharma (ABVC), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does Akari Therapeutics compare to Aytu BioPharma?

Akari Therapeutics (NASDAQ:AKTX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Akari Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. Aytu BioPharma's return on equity of -28.22% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-70.34%	-35.46%
Aytu BioPharma	-39.02%	-28.22%	-5.20%

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 30.7% of Akari Therapeutics shares are held by insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Akari Therapeutics had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Aytu BioPharma. Akari Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Akari Therapeutics	Neutral
Aytu BioPharma	Neutral

Akari Therapeutics currently has a consensus price target of $89.00, suggesting a potential upside of 1,324.00%. Aytu BioPharma has a consensus price target of $9.33, suggesting a potential upside of 273.33%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Aytu BioPharma has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Aytu BioPharma	$66.38M	0.40	-$13.56M	-$3.84	N/A

Akari Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Summary

Akari Therapeutics and Aytu BioPharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Dyadic International has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	9.04	-$7.36M	-$0.25	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Dyadic International presently has a consensus price target of $3.00, suggesting a potential upside of 291.39%. Akari Therapeutics has a consensus price target of $89.00, suggesting a potential upside of 1,324.00%. Given Akari Therapeutics' higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Akari Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. Akari Therapeutics' return on equity of -70.34% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-239.67%	-695.96%	-78.24%
Akari Therapeutics	N/A	-70.34%	-35.46%

In the previous week, Akari Therapeutics had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Akari Therapeutics	Neutral

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 29.5% of Dyadic International shares are held by company insiders. Comparatively, 30.7% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dyadic International has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Summary

Akari Therapeutics beats Dyadic International on 6 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Akari Therapeutics has a consensus price target of $89.00, suggesting a potential upside of 1,324.00%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Akari Therapeutics' return on equity of -70.34% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Akari Therapeutics	N/A	-70.34%	-35.46%

In the previous week, Virios Therapeutics and Virios Therapeutics both had 1 articles in the media. Virios Therapeutics' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 30.7% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Summary

Akari Therapeutics beats Virios Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

ABVC BioPharma has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 30.7% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ABVC BioPharma's return on equity of -65.11% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-65.11%	-40.13%
Akari Therapeutics	N/A	-70.34%	-35.46%

Akari Therapeutics has a consensus price target of $89.00, indicating a potential upside of 1,324.00%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Akari Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Akari Therapeutics	Neutral

ABVC BioPharma has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.88	-$7.91M	-$0.40	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Summary

Akari Therapeutics beats ABVC BioPharma on 7 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Marker Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Akari Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akari Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Akari Therapeutics' return on equity of -70.34% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-70.34%	-35.46%
Marker Therapeutics	-343.03%	-80.86%	-67.04%

Akari Therapeutics currently has a consensus price target of $89.00, indicating a potential upside of 1,324.00%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 584.93%. Given Akari Therapeutics' higher probable upside, research analysts clearly believe Akari Therapeutics is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Akari Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Marker Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Akari Therapeutics	Neutral
Marker Therapeutics	Neutral

Marker Therapeutics has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A

Summary

Akari Therapeutics beats Marker Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTX vs. The Competition

Export

Metric	Akari Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.53M	$3.37B	$6.25B	$12.12B
Dividend Yield	N/A	2.25%	2.78%	5.20%
P/E Ratio	N/A	15.36	20.64	25.39
Price / Sales	N/A	298.52	534.02	75.96
Price / Cash	N/A	124.38	43.29	53.47
Price / Book	0.25	7.32	9.98	6.81
Net Income	-$17.30M	$24.17M	$3.54B	$333.04M
7 Day Performance	14.26%	2.10%	3.50%	3.15%
1 Month Performance	59.44%	4.39%	4.17%	7.12%
1 Year Performance	-87.60%	78.56%	41.85%	41.21%

Akari Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	2.1489 of 5 stars	$6.25 -5.0%	$89.00 +1,324.0%	N/A	$7.53M	N/A	N/A	9
AYTU Aytu BioPharma	1.8108 of 5 stars	$2.57 +0.8%	$9.33 +263.2%	N/A	$27.37M	$66.38M	N/A	160	Upcoming Earnings
DYAI Dyadic International	2.1404 of 5 stars	$0.77 +2.5%	$3.00 +289.6%	N/A	$27.36M	$3.09M	N/A	7	Upcoming Earnings
VIRI Virios Therapeutics	N/A	$1.41 -3.4%	N/A	N/A	$27.15M	N/A	N/A	5
ABVC ABVC BioPharma	0.2348 of 5 stars	$1.03 -1.9%	N/A	N/A	$26.71M	$510K	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akari Therapeutics (AKTX) Competitors

AKTX vs. AYTU, DYAI, VIRI, ABVC, and MRKR

How does Akari Therapeutics compare to Aytu BioPharma?

Summary

How does Akari Therapeutics compare to Dyadic International?

Summary

How does Akari Therapeutics compare to Virios Therapeutics?

Summary

How does Akari Therapeutics compare to ABVC BioPharma?

Summary

How does Akari Therapeutics compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akari Therapeutics (AKTX) Competitors

AKTX vs. AYTU, DYAI, VIRI, ABVC, and MRKR

How does Akari Therapeutics compare to Aytu BioPharma?

Is AKTX or AYTU more profitable?

Do insiders and institutionals hold more shares of AKTX or AYTU?

Does the media favor AKTX or AYTU?

Do analysts recommend AKTX or AYTU?

Which has stronger earnings and valuation, AKTX or AYTU?

Which has more volatility & risk, AKTX or AYTU?

Summary

How does Akari Therapeutics compare to Dyadic International?

Which has higher valuation & earnings, DYAI or AKTX?

Do analysts recommend DYAI or AKTX?

Is DYAI or AKTX more profitable?

Does the media refer more to DYAI or AKTX?

Do institutionals and insiders believe in DYAI or AKTX?

Which has more volatility and risk, DYAI or AKTX?

Summary

How does Akari Therapeutics compare to Virios Therapeutics?

Which has higher valuation & earnings, VIRI or AKTX?

Do analysts recommend VIRI or AKTX?

Is VIRI or AKTX more profitable?

Does the media refer more to VIRI or AKTX?

Do institutionals and insiders believe in VIRI or AKTX?

Which has more volatility and risk, VIRI or AKTX?

Summary

How does Akari Therapeutics compare to ABVC BioPharma?

Which has more risk & volatility, ABVC or AKTX?

Do insiders & institutionals believe in ABVC or AKTX?

Is ABVC or AKTX more profitable?

Do analysts rate ABVC or AKTX?

Does the media prefer ABVC or AKTX?

Which has higher valuation & earnings, ABVC or AKTX?

Summary

How does Akari Therapeutics compare to Marker Therapeutics?

Which has more volatility and risk, AKTX or MRKR?

Do institutionals & insiders believe in AKTX or MRKR?

Is AKTX or MRKR more profitable?

Do analysts recommend AKTX or MRKR?

Does the media prefer AKTX or MRKR?

Which has stronger earnings & valuation, AKTX or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools